Royalty Report: Drugs, Therapeutic, Disease – Collection: 233152

License Grant

The Licensor grants to the Cayman Island Licensee and its Affiliates a sole and exclusive  royalty-bearing license, with the right to sublicense, under the Licensor IP and rights in the Product IP, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Compounds and Products in the Field in the Territory.  The License provides exclusive rights to and use of the Licensors patent portfolio of Apo E mimetic peptides and formulations, which have anti-inflammatory properties, in the territory.

License Property

Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides.

Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases.

Field of Use

Field means all diagnostic, therapeutic and prophylactic uses for all indications, except for the diseases of the eye.

License Grant

The University grants the Licensee an exclusive right and license to practice, commercialize and otherwise exploit the Licensed Patents and grants the exclusive right and license to make, have made, research, develop, use, lease, offer to sell, sell, import and export Licensed Products, within the Licensed Field of Use in the Licensed Territory during the term.
The Licensee has the right to grant sublicenses.

License Property

The licensee covers AEM-28 and certain analogs.

U.S. Patent No. 6,156,727. Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis.
U.S. Patent No 6,506,880. Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol.
U.S. Patent No. 7,653,771. Synthetic single domain polypeptides mimicking apolipoprotien F, Anantharamaiah.

Apolipoprotein E (Apo E) is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E that contains a domain that anchors into a lipoprotein surface while also providing the Apo E binding domain that is removed by heparin sulfate receptors in the liver. AEM-28 as an Apo E mimetic has the potential to restore the ability of atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia or HoFH), have Severe Refractory Hypercholesterolemia, or have acute coronary syndrome, AEM-28 may provide a therapeutic solution.

Field of Use

Licensed Field of Use means any and all diagnostic, therapeutic and prophylactic uses in all fields of use, and for all indications except diseases of the eye.

License Grant

The University grants an exclusive, even as to the University, world-wide license to research, develop, commercialize, make, have made, use, import, offer for sale and sell under the University Existing Patents and New Patents, Licensed Products and Materials in all fields during the Term, and under the Assigned Bristol-Myers Squibb Patents and Assigned BMS Technical Information, the Designated Compounds and University Materials in the Field of Use during the Term.

License Property

The patents include Composition Patents, Combination Patents, and, Universitys Existing and New Patents.

Designated Compound means: BMS-201,038;  prodrugs or metabolites of BMS-201,038, to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and  stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds; furthermore, in the case of a prodrug or metabolite as referred to above, the compound in question will constitute a Designated Compound hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of BMS-210,038 within the Field of Use.

The University completed a Phase II clinical trial of lomitapide for the treatment of patients with called homozygous familial hypercholesterolemia, or HoFH.

Field of Use

Field of Use means:  monotherapy or in combination with other dyslipidemic therapies for treatment of patients with homozygous familial hypercholesterolemia; monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypercholesterolemia of any etiology unable to come within 15% of NCEP LDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; (c) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe combined hyperlipidemia of any etiology unable to come within 15% of NCEP non-HDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; and (d) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypertriglyceridemia unable to reduce TG<1000 on maximal tolerated therapy.

Licensee's lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor, or MTP-I, which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. Licensee is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.  These patients are at very high risk of experiencing life threatening events at an early age as a result of extremely elevated cholesterol levels in the blood. Licensee believe that lomitapide, either on a stand-alone basis or in combination with other drugs, has the potential to help these patients achieve recommended target levels of low-density lipoprotein cholesterol, or LDL-C.

License Grant

The University hereby grants to Licensee an exclusive license to research, develop, make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law. Licensee will not make, use, have made, sell, offer for sale, or import Licensed Products outside the Field of Use.

License Property

1. “Humanin and Humanin Analogues to treat T2DM ” (UCLA Case No. 2007-526)(U.S. Patent Application 12/451,524); and

2. “ Humanin and Humanin Analogues to treat T1DM” (UCLA Case No. 2007-714)(Issued US Patent 7,998,928 and U.S. Patent Application 13/180,181);

3. “SHLPs” (UCLA Case No. 2008-488)(U.S. Patent Application 12/989,688); and

4. “Humanin and analogues for atherosclerosis” (UCLA Case No. 2011-331)(U.S. Provisional Patent Application 61/498,474).

Licensed Product means any article, composition, apparatus, substance, chemical, or any other material covered by a Valid Claim within The University’s Patent Rights or whose manufacture, import use, offer for sale, or sale would, absent the license granted under this Agreement, constitute an infringement, inducement of infringement or contributory infringement of any Valid Claim within The University's Patent Rights, or any service, article, composition, apparatus, chemical, substance or any other material made, used or sold by or utilizing or practicing a Licensed Method. If the Licensed Product is a component of another product such as a kit, composition of matter or combination, such kit, composition of matter or combination is deemed to be the Licensed Product for purposes of this Agreement.

T2DM is Type 2 Diabetes Mellitus which is a chronic metabolic disease that affects the body’s ability to turn food into energy. Normally, after eating, sugar in the form of glucose from the food enters the bloodstream. The hormone Insulin, released from the pancreas in response to the rising levels of glucose in the bloodstream, is responsible for transporting the glucose into the body’s cells, to be used as fuel.

T1DM is Type 1 Diabetes Mellitus which is a chronic illness characterized by the body’s inability to produce insulin due to the autoimmune destruction of the beta cells in the pancreas. Onset most often occurs in childhood, but the disease can also develop in adults in their late 30s and early 40s.

Atherosclerosis is a disease in which plaque (plak) builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can lead to serious problems, including heart attack,stroke or even death.

Field of Use

Field of Use means all fields, including but not limited, to therapeutics and diagnostics.

License Grant

The University has an assignment of an invention describing approaches to identify novel candidate genes implicated in the development of atherosclerosis, which represent likely targets for future novel diagnostic and therapeutic strategies and the University grants the Licensee an exclusive worldwide license under the Licensed Patent in the exclusive licensed Field of Use to make, have made, use, offer for sale, sell, import, Licensed Product and practice any method or procedures and to have any of the foregoing performed on its behalf by a third party in the Licensed territory including the right to subLicense.

License Property

Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano). It is commonly referred to as a hardening or furring of the arteries. It is caused by the formation of multiple plaques within the arteries.

Field of Use

Term Limited Field Of Use means any and all nontherapeutic applications such as diagnostic use and research reagents.

License Grant

Licensor of Belgium hereby grants Licensee an exclusive, worldwide license under the Patent Rights and Know-How to develop, make, use, import, offer for sale and sell, and to have developed, made, used, imported, offered for sale and sold, the Licensed Products.  Licensee shall be entitled to grant sublicenses.

License Property

Compound means Pro-Apolipoprotein A-I.

Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoprotein (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoprotein (HDL), (see apoA-1 Milano).

Field of Use

Licensee, a company specialized in novel therapies for patients with atherosclerosis and related metabolic disorders, has an interest in acquiring exclusive rights to such patent rights, proprietary information and know-how with respect to the Compound.

License Grant

The German Licensor grants a non-transferable, exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements. The foregoing license grant includes the right to make reference to all regulatory approvals, data, filings and correspondence, including DMFs contained within the Licensor Know-How.

License Property

Licensor has been engaged in the development of implitapide as an inhibitor of microsomal triglyceride transfer protein.

Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.

Field of Use

Licensee is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders.

Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both.  Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.

License Grant

The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.

License Property

Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases: peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

Field of Use

Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases: peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

License Grant

The Licensee, as part of a strategic alliance, entered into an agreement with the Belgium Licensor.

The Licensor granted the Licensee an exclusive, worldwide, royalty-bearing license to MBX-8025 and certain other PPAR compounds (the PPAR Products) with the right to grant sublicenses to third parties to make, use and sell such PPAR Products.

License Property

PPAR – Peroxisome proliferator-activated receptors form a family of nuclear hormone receptors involved in energy hemostasis and lipid metabolism.

MBX-8025 is a selective agonist (a substance that stimulates a response by binding to a receptor) for the peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes involved in lipid storage and transport (particularly in fatty acid oxidation) and insulin signaling and sensitivity. In preclinical studies in rodents, dogs and primates, MBX-8025 demonstrated a variety of beneficial effects on the lipid profile and other metabolic parameters. MBX-8025 treatment increased peripheral oxidation of fatty acids leading to reduced levels of triglycerides (TGs) and low-density lipoprotein (LDL), while raising high-density lipoprotein (HDL). MBX-8025 inhibited fat mass accumulation, resulting in attenuation of body weight gain in rodent models of obesity.

MBX-8025 has potential therapeutic application for disorders linked to deficits in lipid storage, handling and utilization, many of which result in metabolic disorders. To date, it has been in development as a first-in-class treatment that effectively addresses all three lipid disorders associated with mixed dyslipidemia (abnormal lipid levels in the blood) as well as a majority of the cardiovascular risk factors that define metabolic syndrome. The future development program will focus on high unmet need indications in dyslipidemia as well as in high unmet need specialty and orphan diseases.

The 8-week Phase 2 study investigated MBX-8025 at doses of 50 or 100 mg/day in moderately obese patients with mixed dyslipidemia. The study demonstrated that treatment with MBX-8025 led to significant reductions in total LDL (~20%) and selective depletion of the small dense atherogenic (promotion of arterial plaque formation) LDL particles, resulting in an exceptional improvement in the LDL particle size profile. It also decreased TGs (~30%) and raised HDL (~12%). This unique combination of effects significantly decreased the atherogenic risk of patients’ lipid profile. When administered in combination with atorvastatin (Lipitor®), MBX-8025 provided a comprehensive improvement in all lipid and cardiovascular risk parameters without side effects seen in other combination lipid therapies.

In addition, MBX-8025 addressed other aspects of metabolic syndrome, including improvements in insulin sensitivity and trends toward decreased waist circumference and body fat. Over half of the patients that entered the Phase 2 study meeting the criteria for metabolic syndrome no longer met the criteria at the end of the study.

The product seladelpar is for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver. Seladelpar is a potent and selective agonist of PPARd, a nuclear receptor that regulates genes important for lipid, bile acid/sterol and glucose metabolism and for inflammation in liver and muscle.

Field of Use

This agreement pertains to the drug industry relating to treatment of an autoimmune disease.

Under the terms of the agreement, the Licensee has full control and responsibility over the research, development and registration of any PPAR Products and is required to use diligent efforts to conduct all such activities.

The Licensee shall grant the Licensor a worldwide, exclusive, irrevocable license under the agreement in all information that is controlled, developed or acquired by the Licensee which relates to a PPAR compound or PPAR product and in all patents that are filed.

License Grant

This amendment between the French Licensor and the Licensee of the Netherlands will modify the financial terms associated with royalty payments and create reporting obligations regarding pricing and reimbursement of Licensees gene therapy product Glybera® and its development milestones, and add a Right of First Negotiation for Licensor.  The original agreement was exclusive.

License Property

The original agreement identifies the patents are relating to the preparation and use of recombinant viruses in gene therapy.

The Product shall mean a gene therapy product containing a recombinant virus with a nucleic acid coding for a lipoprotein lipase (LPL) developed, used and/or commercialized by or for Licensee or its affiliates where the activity in relation to such product occurs in one of the countries of the Territory and is covered in whole or in part by a Valid Claim within the Patents in that country.

Field of Use

The Field of Use shall mean indications of Lipoprotein Lipase (LPL) deficiency also referred to as Type I or V hyperlipoproteinernia.

Lipoprotein lipase deficiency (LPLD) is a rare monogenic disorder of triglyceride metabolism. Deficiency of the enzyme lipoprotein lipase results in pronounced accumulation of triglycerides in the plasma. Specifically, the clearance of chylomicrons is impaired. Chylomicrons, fatty droplets that transport fat in the form of triglyceride, appear in the bloodstream shortly after the ingestion of dietary fat. Chylomicrons are normally cleared from the body after a period of fasting. Lipoprotein lipase recognizes a protein in chylomicrons called apolipoprotein C2, and is then activated to metabolize and clear out triglycerides. However, deficiency or lack of lipoprotein lipase results in the accumulation of chylomicrons and triglycerides in the body. High triglyceride levels are present from infancy and childhood, and various associated symptoms may occur. Some patients remain undiagnosed until adulthood. LPLD is caused by mutations in the LPL gene and is inherited in an autosomal recessive manner.

Glybera is used to treat adults with lipoprotein lipase deficiency who have severe or multiple attacks of pancreatitis (inflammation of the pancreas) despite maintaining a low-fat diet.  This is a type of medicine that works by delivering genes into the body.

License Grant

Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensed Compound Patent Rights, the Licensed Compound Know-How and Licensors interest in the Joint Patent Rights, to make, have made, use, develop, sell, offer for sale, have sold, import and export Products.

Licensor grants an option, the License Option, to acquire a worldwide, nonexclusive, or to the extent available, exclusive license, with the right to sublicense, under some or all of the Additional Patent Rights and the Additional Know-How to make, have made, use, develop, sell, offer for sale, have sold, import and export Products.

License Property

Licensor is a drug discovery company that has expertise and proprietary technology relating to compounds that modulate the Farnesoid X Receptor.

Licensed Compound means any Existing Compound or any Derivative. Any Licensed Compound shall also include any salt, metabolite, prodrug, constitutional or geometric isomer, regioisomer, stereoisomer including any enantiomer or diastereoisomer, salt form, hydrate, solvate, polymorph or other physical form of any such compound.

Bioisosteric Scaffold means any scaffold that is: bioisosteric to a Licensor Agreement Scaffold and Controlled by Licensee.

Field of Use

This agreement is related to compounds targeting the farnesoid X receptor, or FXR, a nuclear hormone receptor implicated in a variety of metabolic and liver disorders.

Licensee is a multinational health care company that has expertise and capability in developing and marketing human pharmaceuticals and has research and development programs.

Farnesoid X receptor is a nuclear receptor that is encoded by the NR1H4 gene in humans.

XL335 targets the Farnesoid X Receptor (FXR) and has been shown to function as a bile acid receptor regulating genes involved in lipid, cholesterol and bile acid homeostasis. We have identified proprietary, potent and selective FXR ligands (a compound that binds to a receptor) that have good oral bioavailability and drug metabolism and pharmacokinetic properties. In rodent models of dyslipidemia, these compounds lowered triglycerides by decreasing triglyceride synthesis and secretion. In addition, they improved the high-density lipoprotein (HDL)/low-density lipoprotein (LDL) ratio and are anti-atherogenic (preventing the formation of lipid deposits in the arteries) in animal models of atherosclerosis. XL335 is also effective in models of cholestasis (a condition in which bile excretion from the liver is blocked), cholesterol gallstones and liver fibrosis. These data suggest that small molecule ligands targeting FXR should function as novel therapeutic agents for treating symptoms and disease states associated with metabolic syndrome as well as certain liver disorders.

License Grant

Licensor grants the Licensee of Japan exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan.

License Property

NEXLETOL and NEXLIZE are cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines.

Field of Use

The field of use is for hypercholesterolemia patients in Japan.  Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).  High cholesterol can limit blood flow, increasing risk of heart attack or stroke.

License Grant

The Licensor has granted the Licensee a non-revocable and exclusive worldwide license including the right to sublicense to third parties to the patents necessary to develop and commercialize drug candidates in which Cardio Vascu-Grow is the active ingredient. As a part of that agreement, Licensor will provide technical development services to us for the development and regulatory approvals of our drug candidates, including but not limited to, lab work, testing and production of our drug candidates in which Cardio Vascu-Grow is the active ingredient for clinical trials, all as directed by us.

License Property

We are working closely with an affiliated company, Cardio, pursuant to a joint patent and technology sharing agreement, to manufacture human fibroblast growth factor-1 (Cardio Vascu-Grow) for Cardio’s ongoing clinical trials.

Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients.  Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).

Issued US Patents:
1. U.S. 6,268,178 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;” and
2. U.S. 6,642,026 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”
3. U.S. 6,773,899 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides”;
4. U.S. 6,794,162, entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;”
Pending US Patent Applications 1.. U.S. 10/649,480 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;” published as US Patent Application No. US 2004/0115769

License Grant

The Swedish Licensee and the Licensor desire to establish a collaboration to apply such Licensor technology and expertise to the identification and characterization of biochemical pathways and targets in specific research areas relevant to metabolic syndrome and Alzheimers disease, and to provide for the development and commercialization of novel prophylactic and therapeutic products based on such research.

Licensor grants an exclusive, worldwide license under the Pre-existing Technologies and Sole Inventions Controlled by Licensor and under Licensors interest in the Joint Inventions to use each Selected Target to search for Collaboration Compounds directed at such Selected Target for activity within the Applicable Field, to develop, for use in the Applicable Field, Products comprising or incorporating such Collaboration Compounds, to develop, following, such Product for any human indication, and to make, have made, use, sell, offer to sell and have sold such Products.

License Property

The Pre-existing Technologies means any and all inventions, developments, results, know-how and other Information, and all intellectual property relating thereto, made, created or invented by a Party.

The Sole Inventions means any and all inventions, developments, results, know-how and other Information, and all intellectual property relating thereto, made, discovered or developed solely by a Party.

Homolog is a gene or gene product that has homology to a Selected Target.

Licensor is a biotechnology company that has expertise and proprietary technology relating to genetic model systems, genomics and computational biology and is applying such technology to discover and validate targets for drug discovery in a variety of disease areas, including metabolic syndrome and Alzheimers disease.

Field of Use

This agreement is for either the Field of Alzheimers Disease or the Field of Metabolic Syndrome.

Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.

Licensee is a multinational health care company that has expertise and capability in developing and marketing human pharmaceuticals and has research and development programs in the areas of, inter alia, metabolic syndrome and Alzheimers disease.

License Grant

The License Agreement grants us a non-exclusive, non-transferable and non-assignable License to use Licensor’s patents, trademarks and technology rights relating to the licensed products and the processing and reporting of laboratory analyses of samples collected using the products.

License Property

The products licensed are: Cholesterol Panel; Hemoglobin A1c; Prostate Screen; Thyroid Test and Anemia Test.

Cholesterol Panel (a lipid profile consisting of total cholesterol, high density cholesterol, low density cholesterol and triglycerides).  This Cholesterol Panel is the first self-collected lipid profile for dried blood sample analysis that satisfies the National Cholesterol Education Program’s rigorous performance standards. It is used in the management and determination of coronary heart disease.

Hemoglobin A1c (a test that meets the certification standards of the National Glycohemoglobin Standardization Program). This test is critical for proper blood sugar monitoring and regulation by persons affected with diabetes.

Prostate Screen (a test to determine blood levels of prostate specific antigen). This test is used to help determine abnormal prostate conditions, such as prostate cancer.

Thyroid Test (a test to determine blood levels of thyroid stimulating hormone). This test is used to help determine thyroid dysfunction and to successfully manage treatment regimens.

Anemia Test (a rapid response test – like a home pregnancy test, the results are available to the user immediately – for low hemoglobin levels). This test is used to monitor and identify the onset or change in hemoglobin levels, which is a common side effect for many disease states including HIV, chronic kidney disease and cancer.

Field of Use

Products specialize in the use of micro-sample blood transportation devices and unique scientific procedures for the clinical testing of these micro-blood samples.

License Grant

The Inventors grant the Company:
—  an exclusive, worldwide license, with the right to grant sublicenses, under the Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise dispose of the Licensed Products in the Field, and
—  subject to any pre-existing rights of third Persons, a non-exclusive worldwide license, with the right to grant sublicenses, under the Know-How to make, have made, use, import, offer for sale, sell and otherwise dispose of the Licensed Products in the Field.

License Property

The know-how and property is for compositions and uses of peptide mimetics of Apoprotein A-I.  The patent is for Apolipoprotein A-1 Agonists and their use to treat dyslipidemic disorders.

Field of Use

The Field means Apoprotein A-I mimetics as described in the Licensed Patents for the diagnosis and/or treatment of atherosclerosis and related metabolic diseases.

Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries.  Atherosclerosis is the primary cause of coronary artery disease (CAD) and stroke, with multiple genetic and environmental contributions.